E. Fougera & Co. will celebrate its sesquicentennial this year, the Long Island, NY-based generic pharmaceuticals company announced.
E. Fougera & Co. will celebrate its sesquicentennial this year, the Long Island, NY-based generic pharmaceuticals company announced.
The company kicked off its celebration by donating two $2,500 grants to pharmacy degree programs at two local colleges, The Arnold and Marie Schwartz College of Pharmacy at Long Island University and the College of Pharmacy and Allied Health Professionals at St. John's University. The gifts will be used to support students who demonstrate academic achievement, financial need and service to the profession and/or the community.
The company, one of Long Island's largest employers, has always had local ties. Edmond Fougera, a French immigrant, founded it in Brooklyn in 1849. His business began as a pharmacy specializing in European imports and was the first pharmacy to introduce Americans to petroleum jelly.
By 1918, it developed a reputation as the country's "largest wholesale importing house for French and other foreign medicinal preparations and specialties," according to a 1918 article in The Brooklyn Eagle, the local news rag.
In the 1930s and 1940s, Fougera began specializing in the dermatological and urological markets, and it deployed a national sales force. By 1963, the company had attracted the attention of a German company called Byk Gulden GMBH, and the German company acquired Fougera. In 1966, the company entered the generic pharmaceutical market.
Over the course of the past 30 years, Fougera has focused on manufacturing and selling generic creams and ointments, such as Surgilube, Diflorasone Diacetate Cream, Hydrocortisone Rx and Vitamin A & D Ointment. Five of its products are ranked first in market share.
"If you open your medicine cabinet, chances are you will find a Fougera product right there on the shelf," said Stuart Schansinger, the company's buying group sales manager. "We are extremely proud of what we have achieved over our long history, from our roots as a retail pharmacy to our present role as a major generic pharmaceutical manufacturer." PR
The Future of Fertility: AI, Personalized Medicine, and Ethical Considerations
January 30th 2025Dr. Lawrence B. Werlin, MD, FACOG of HRC Fertility (@md.lawrence.werlin on TikTok), discusses how to combat the spread of misinformation on social media, opportunities that social media presents, advancements in fertility technology, and more.
FDA Approves Roche’s Susvimo Refillable Eye Implant for Diabetic Macular Edema
February 4th 2025Roche’s Susvimo, a refillable eye implant for diabetic macular edema, provides continuous delivery of ranibizumab, showing sustained vision improvements with fewer treatments than standard eye injections.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.